Sarepta Therapeutics Inc. News
The Sarepta Therapeutics Pipeline No One is Talking About
Gene therapy and gene editing get all the glory, but investors shouldn't overlook an emerging group of tools.
Why Wall Street Doubts This Biotech Penny Stock Will Be Delisted
The share price dipped below $1 -- into penny stock territory -- but analysts are optimistic they'll recover.
Barclays Lists Halliburton, Dick's, Ally as 2022 Earnings Winners
Barclays made a list of 35 stocks with overweight ratings that it expects to benefit from strong earnings next year.
Sarepta Higher After Progress With Muscular Dystrophy Drug Trial
Sarepta's trial supports its drug's 'potentially differentiated profile' to treat Duchenne muscular dystrophy, the company said. The stock is higher.
Boeing, Micron, Pfizer, Sarepta - Friday's Premarket Movers
Stocks moving in premarket trading Friday include Boeing, Micron, Pfizer, Sarepta and Moderna.
Sarepta Sinks on Disappointing Gene-Therapy Study Results
Sarepta shares lose half their value after a gene-therapy study seen as a shoo-in treatment for Duchenne muscular dystrophy produces disappointing results.
Headlight Stocks: Cramer's 'Mad Money' Recap (Wednesday 8/5/20)
Cramer says buyers are betting science will beat the virus. Here are the companies that can light the way forward.
Boeing, 'Rise of Skywalker,' Sarepta, Dow Futures, Trade Optimism - 5 Things You Must Know Monday
U.S. stocks are poised to again hit fresh record highs as optimism rises around the 'phase one' trade agreement between the United States and China; Boeing's Starliner returns to Earth; 'The Rise of Skywalker' makes $175.5 million at the weekend box office but still disappoints.
Sarepta Therapeutics Surges on FDA Approval of Muscular Dystrophy Treatment
Shares soar after the biotech company receives fast-track approval for its injectable treatment for Duchenne muscular dystrophy.
Sarepta Shares Rise on Positive Gene Therapy Trial Results
The nine-month results showed improvements for three clinical trial participants with Limb-girdle muscular dystrophy.
Tesla Stock Higher As Investors Look Past July China Sales Slump
Tesla sold just over 28,000 China-made cars last month, an industry lobby group said Tuesday.
Novavax Stock Plummets After Slashing 2022 Vaccine Sales Forecast
"I believe we were late to the market and US vaccination was driven by what was available and shown to work," said Novavax CEO Stanley Erck.
Real Estate Titan Zillow Sees Tough Times Ahead in Housing
The residential real estate market has stumbled, after soaring in the first 18 months of the covid pandemic.
After Record Losses, a Fund's Leader Looks to Samurai History
SoftBank's Vision Fund lost nearly $22 billion in the latest quarter.